GlassScriptPhysician profile
John P Josupait
NPI 1972594018
$3,576.73
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $515 · 2021: $801 · 2022: $808 · 2023: $755 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.27 | 2019-2022 | |
| Pfizer INC. | $302.95 | 2019-2023 | |
| Astellas Pharma US INC | $235.64 | 2022-2024 | Veozah |
| Amgen INC. | $233.41 | 2019-2024 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $209.86 | 2021-2023 | |
| Therapeuticsmd, INC. | $208.60 | 2019-2022 | |
| Agile Therapeutics, INC. | $192.92 | 2021 | |
| Hologic Sales and Service, LLC | $190.76 | 2020-2022 | |
| Myovant Sciences INC. | $136.06 | 2021-2022 | |
| Coopersurgical, INC. | $129.18 | 2019-2023 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $123.86 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $122.61 | 2023-2024 | Myfembree |
| Dysis Medical, INC. | $119.74 | 2019-2022 | |
| Organon LLC | $110.26 | 2021-2023 | Nexplanon |
| Avion Pharmaceuticals | $95.40 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $86.46 | 2020-2023 | Slynd |
| Aspira Women'S Health INC | $65.30 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.21 | 2019-2020 | |
| Allergan, INC. | $60.73 | 2019-2020 | |
| Novo Nordisk INC | $51.04 | 2022-2024 | Wegovy |
| Daiichi Sankyo INC. | $50.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.61 | 2019-2022 | |
| Evofem Biosciences, INC. | $40.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.57 | 2022 | |
| Meditrina | $38.74 | 2022-2023 | |
| Duchesnay USA Incorporated | $28.03 | 2019 | |
| Medtronic, INC. | $27.64 | 2021 | |
| Becton, Dickinson and Company | $25.31 | 2024 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $20.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.75 | 2023 | Quviviq |
| Shield Therapeutics INC | $14.56 | 2023 | Accrufer |
| Boston Scientific Corporation | $14.38 | 2019 | |
| Lupin INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Josupait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.